Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786956 | 0.92 | MAPT (0.59) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL1036349 | 0.92 | MAPT (0.59) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL29660879 | 0.88 | TDP1 (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6448598 | 0.88 | SMN1; SMN2 (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL12939114 | 0.88 | TDP1 (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL166437 | 0.88 | TDP1 (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL12659540 | 0.86 | MAPT (0.53) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL12939162 | 0.86 | MAPT (0.53) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL12659923 | 0.86 | L3MBTL1 (0.53) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL19326705 | 0.84 | MAOB (0.60) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MAPT 2805/4885TDP1 4550/4885L3MBTL1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.